Trial Profile
Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 23 Mar 2019
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin; Paclitaxel
- Indications Oesophageal cancer
- Focus Therapeutic Use
- 04 Mar 2015 Planned primary completion date changed to 1 Jan 2016 as reported by ClinicalTrials.gov record.
- 04 Mar 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record
- 12 Feb 2014 New trial record